Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1595043 (Double-blind, Randomised, Placebocontrolled, Parallel Group Design) in Healthy Male Subjects
Latest Information Update: 23 Feb 2024
At a glance
- Drugs BI 1595043 (Primary) ; Midazolam
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 18 Jan 2022 Status changed from active, no longer recruiting to completed.
- 20 Dec 2021 Planned End Date changed from 19 Dec 2021 to 27 Dec 2021.
- 20 Dec 2021 Planned primary completion date changed from 19 Dec 2021 to 27 Dec 2021.